Structure of ASTX029

oral ERK1/2 kinase and phosphorylation inhib

Ph. 1/2 candidate for solid tumors

from SBDD from prior lead

Journal of Medicinal Chemistry

Astex Pharmaceuticals, Cambridge, UK

The Astex ERK1/2 kinase inhibitor, ASTX029, is an oral Ph. I-II candidate for patients with advanced solid tumors. The molecule was derived from fragment screening together with structure-based design. Interestingly,…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.